Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 297

1.

Cleaved Caspase-3 transcriptionally regulates angiogenesis promoting chemotherapy resistance.

Bernard A, Chevrier S, Beltjens F, Dosset M, Viltard E, Lagrange A, Dérangère V, Oudot A, Ghiringhelli F, Collin B, Apetoh L, Feron O, Chen S, Arnould L, Végran F, Boidot R.

Cancer Res. 2019 Oct 14. pii: canres.0840.2019. doi: 10.1158/0008-5472.CAN-19-0840. [Epub ahead of print]

PMID:
31611309
2.

Trifluridine/tipiracil plus oxaliplatin improves PD-1 blockade in colorectal cancer by inducing immunogenic cell death and depleting macrophages.

Limagne E, Thibaudin M, Nuttin L, Spill A, Dérangère V, Fumet JD, Amellal N, Peranzoni E, Cattan V, Ghiringhelli F.

Cancer Immunol Res. 2019 Oct 14. pii: canimm.0228.2019. doi: 10.1158/2326-6066.CIR-19-0228. [Epub ahead of print]

PMID:
31611243
3.

[Immunoediting eventually proven in humans. Genetics to assist immunotherapy].

David Fumet J, Ghiringhelli F.

Med Sci (Paris). 2019 Aug-Sep;35(8-9):629-631. doi: 10.1051/medsci/2019125. Epub 2019 Sep 18. French. No abstract available.

PMID:
31532373
4.

Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.

Truntzer C, Isambert N, Arnould L, Ladoire S, Ghiringhelli F.

Eur J Cancer. 2019 Oct;120:97-106. doi: 10.1016/j.ejca.2019.07.020. Epub 2019 Sep 6.

PMID:
31499385
5.

STAT3, a Master Regulator of Anti-Tumor Immune Response.

Rébé C, Ghiringhelli F.

Cancers (Basel). 2019 Aug 30;11(9). pii: E1280. doi: 10.3390/cancers11091280. Review.

6.

Is There a Place for Immunotherapy for Metastatic Microsatellite Stable Colorectal Cancer?

Ghiringhelli F, Fumet JD.

Front Immunol. 2019 Aug 6;10:1816. doi: 10.3389/fimmu.2019.01816. eCollection 2019. Review.

7.

Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study.

Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F.

World J Gastrointest Oncol. 2019 Aug 15;11(8):634-641. doi: 10.4251/wjgo.v11.i8.634.

8.

The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer.

Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, Marisa L, Djouadi F, Poindessous V, Crozet C, Emile JF, Mulot C, Le Malicot K, Boige V, Blons H, de Reynies A, Taieb J, Ghiringhelli F, Bennouna J, Launay JM, Laurent-Puig P, Mouillet-Richard S.

EBioMedicine. 2019 Aug;46:94-104. doi: 10.1016/j.ebiom.2019.07.036. Epub 2019 Jul 31.

9.

Correction: Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.

Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A.

Clin Cancer Res. 2019 Aug 1;25(15):4859. doi: 10.1158/1078-0432.CCR-19-1599. No abstract available.

PMID:
31371309
10.

Inactivation of Proprotein Convertases in T Cells Inhibits PD-1 Expression and Creates a Favorable Immune Microenvironment in Colorectal Cancer.

Tomé M, Pappalardo A, Soulet F, López JJ, Olaizola J, Leger Y, Dubreuil M, Mouchard A, Fessart D, Delom F, Pitard V, Bechade D, Fonck M, Rosado JA, Ghiringhelli F, Déchanet-Merville J, Soubeyran I, Siegfried G, Evrard S, Khatib AM.

Cancer Res. 2019 Oct 1;79(19):5008-5021. doi: 10.1158/0008-5472.CAN-19-0086. Epub 2019 Jul 29.

PMID:
31358531
11.

Hypotonic stress enhances colon cancer cell death induced by platinum derivatives and immunologically improves antitumor efficacy of intraperitoneal chemotherapy.

Demontoux L, Derangère V, Pilot T, Thinselin C, Chevriaux A, Chalmin F, Bouyer F, Ghiringhelli F, Rébé C.

Int J Cancer. 2019 Dec 1;145(11):3101-3111. doi: 10.1002/ijc.32590. Epub 2019 Aug 28.

PMID:
31344262
12.

Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.

Borg C, Mantion G, Boudghène F, Mornex F, Ghiringhelli F, Adenis A, Azria D, Balosso J, Ben Abdelghani M, Bachet JB, Vendrely V, François Y, Conroy T, Rio E, Roullet B, Spaëth D, Quero L, Lakkis Z, Coudert M, Ionescu-Goga M, Tanang A, André T.

Clin Colorectal Cancer. 2019 Sep;18(3):200-208.e1. doi: 10.1016/j.clcc.2019.04.006. Epub 2019 May 3.

PMID:
31311761
13.

Hepatic arterial chemotherapy with raltitrexed and oxaliplatin versus standard chemotherapy in unresectable liver metastases from colorectal cancer after conventional chemotherapy failure (HEARTO): a randomized phase-II study.

Ghiringhelli F, Vincent J, Bengrine L, Borg C, Jouve JL, Loffroy R, Guiu B, Blanc J, Bertaut A.

J Cancer Res Clin Oncol. 2019 Sep;145(9):2357-2363. doi: 10.1007/s00432-019-02970-8. Epub 2019 Jul 4.

PMID:
31273511
14.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J.

Gastric Cancer. 2019 Jul 2. doi: 10.1007/s10120-019-00983-3. [Epub ahead of print]

PMID:
31267360
15.

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination.

Grapin M, Richard C, Limagne E, Boidot R, Morgand V, Bertaut A, Derangere V, Laurent PA, Thibaudin M, Fumet JD, Crehange G, Ghiringhelli F, Mirjolet C.

J Immunother Cancer. 2019 Jun 25;7(1):160. doi: 10.1186/s40425-019-0634-9.

16.

Correction: Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2019 Jul;121(3):283. doi: 10.1038/s41416-019-0512-8.

17.

Regulation of T cell antitumor immune response by tumor induced metabolic stress.

Chalmin F, Bruchard M, Vegran F, Ghiringhelli F.

Cell Stress. 2018 Nov 27;3(1):9-18. doi: 10.15698/cst2019.01.171. Review.

18.

Docosahexaenoic acid inhibits both NLRP3 inflammasome assembly and JNK-mediated mature IL-1β secretion in 5-fluorouracil-treated MDSC: implication in cancer treatment.

Dumont A, de Rosny C, Kieu TL, Perrey S, Berger H, Fluckiger A, Muller T, Pais de Barros JP, Pichon L, Hichami A, Thomas C, Rébé C, Ghiringhelli F, Rialland M.

Cell Death Dis. 2019 Jun 19;10(7):485. doi: 10.1038/s41419-019-1723-x.

19.

Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.

Bidard FC, Kiavue N, Ychou M, Cabel L, Stern MH, Madic J, Saliou A, Rampanou A, Decraene C, Bouché O, Rivoire M, Ghiringhelli F, Francois E, Guimbaud R, Mineur L, Khemissa-Akouz F, Mazard T, Moussata D, Proudhon C, Pierga JY, Stanbury T, Thézenas S, Mariani P.

Cells. 2019 May 28;8(6). pii: E516. doi: 10.3390/cells8060516.

20.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
21.

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab.

Dohan A, Gallix B, Guiu B, Le Malicot K, Reinhold C, Soyer P, Bennouna J, Ghiringhelli F, Barbier E, Boige V, Taieb J, Bouché O, François E, Phelip JM, Borel C, Faroux R, Seitz JF, Jacquot S, Ben Abdelghani M, Khemissa-Akouz F, Genet D, Jouve JL, Rinaldi Y, Desseigne F, Texereau P, Suc E, Lepage C, Aparicio T, Hoeffel C; PRODIGE 9 Investigators and PRODIGE 20 Investigators.

Gut. 2019 May 17. pii: gutjnl-2018-316407. doi: 10.1136/gutjnl-2018-316407. [Epub ahead of print]

PMID:
31101691
22.

Factors influencing patient's perception of long-term treatment with low-molecular-weight heparins for cancer-associated thrombosis: an updated analysis of TROPIQUE, a prospective observational study.

Debourdeau P, Arvers P, Hij A, Bennani H, Desauw C, Falvo N, Ghiringhelli F, Hamadé A, Vedrine L, Farge D.

Support Care Cancer. 2019 May 1. doi: 10.1007/s00520-019-04815-z. [Epub ahead of print]

PMID:
31044304
23.

Partial splenic embolization with Glubran®2/Lipiodol® mixture for oncological patients with hypersplenism-related thrombocytopenia requiring systemic chemotherapy.

Loffroy R, Falvo N, Nakaï M, Pescatori L, Aho-Gléglé S, Gehin S, Berthod PE, Né R, Vincent J, Ghiringhelli F, Midulla M, Chevallier O.

Quant Imaging Med Surg. 2019 Mar;9(3):409-417. doi: 10.21037/qims.2019.03.07.

24.

Deciphering the Roles of Innate Lymphoid Cells in Cancer.

Bruchard M, Ghiringhelli F.

Front Immunol. 2019 Apr 3;10:656. doi: 10.3389/fimmu.2019.00656. eCollection 2019. Review.

25.

Cancer cells induce immune escape via glycocalyx changes controlled by the telomeric protein TRF2.

Cherfils-Vicini J, Iltis C, Cervera L, Pisano S, Croce O, Sadouni N, Győrffy B, Collet R, Renault VM, Rey-Millet M, Leonetti C, Zizza P, Allain F, Ghiringhelli F, Soubeiran N, Shkreli M, Vivier E, Biroccio A, Gilson E.

EMBO J. 2019 Jun 3;38(11). pii: e100012. doi: 10.15252/embj.2018100012. Epub 2019 Apr 18.

PMID:
31000523
26.

Anti-MEK and Anti-EGFR mAbs in RAS-Mutant Metastatic Colorectal Cancer: Case Series and Rationale.

Ledys F, Derangère V, Réda M, Guion JF, Milliex R, Roux V, Limagne E, Arnould L, Bengrine L, Ghiringhelli F, Rébé C.

Adv Ther. 2019 Jun;36(6):1480-1484. doi: 10.1007/s12325-019-00949-y. Epub 2019 Apr 12.

PMID:
30980281
27.

Activity and Safety of Palbociclib in Patients with Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Biomarker-driven Phase II Study.

Toulmonde M, Blay JY, Bouche O, Mir O, Penel N, Isambert N, Duffaud F, Bompas E, Esnaud T, Boidot R, Geneste D, Ghiringhelli F, Lucchesi C, Bellera CA, Le Loarer F, Italiano A.

Clin Cancer Res. 2019 Aug 1;25(15):4611-4615. doi: 10.1158/1078-0432.CCR-18-3127. Epub 2019 Apr 12. Erratum in: Clin Cancer Res. 2019 Aug 1;25(15):4859.

PMID:
30979737
28.

T cell Bispecific Antibodies in Node-Positive Breast Cancer: Novel Therapeutic Avenue for MHC class I Loss Variants.

Messaoudene M, Mourikis TP, Michels J, Fu Y, Bonvalet M, Lacroix-Trikki M, Routy B, Fluckiger A, Rusakiewicz S, Roberti MP, Cotteret S, Flament C, Poirier-Colame V, Jacquelot N, Ghiringhelli F, Caignard A, Eggermont AMM, Kroemer G, Marabelle A, Arnedos M, Vicier C, Dogan S, Jaulin F, Sammut SJ, Cope W, Caldas C, Delaloge S, McGranahan N, André F, Zitvogel L.

Ann Oncol. 2019 Mar 29. pii: mdz112. doi: 10.1093/annonc/mdz112. [Epub ahead of print]

PMID:
30924846
29.

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F.

Oncoimmunology. 2019 Jan 22;8(4):e1564505. doi: 10.1080/2162402X.2018.1564505. eCollection 2019.

30.

Cell lines and immune classification of glioblastoma define patient's prognosis.

Klopfenstein Q, Truntzer C, Vincent J, Ghiringhelli F.

Br J Cancer. 2019 Apr;120(8):806-814. doi: 10.1038/s41416-019-0404-y. Epub 2019 Mar 22.

31.

Modal instabilities in high power fiber laser oscillators.

Scarnera V, Ghiringhelli F, Malinowski A, Codemard CA, Durkin MK, Zervas MN.

Opt Express. 2019 Feb 18;27(4):4386-4403. doi: 10.1364/OE.27.004386.

PMID:
30876058
32.

HSP70 is a negative regulator of NLRP3 inflammasome activation.

Martine P, Chevriaux A, Derangère V, Apetoh L, Garrido C, Ghiringhelli F, Rébé C.

Cell Death Dis. 2019 Mar 15;10(4):256. doi: 10.1038/s41419-019-1491-7.

33.

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

Macaire P, Morawska K, Vincent J, Quipourt V, Marilier S, Ghiringhelli F, Bengrine-Lefevre L, Schmitt A.

Eur J Cancer. 2019 Apr;111:116-125. doi: 10.1016/j.ejca.2019.01.102. Epub 2019 Mar 5.

PMID:
30849685
34.

Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer.

Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F.

World J Clin Oncol. 2019 Feb 24;10(2):75-85. doi: 10.5306/wjco.v10.i2.75.

35.

Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).

Adenis A, Bennouna J, Etienne PL, Bogart E, Francois E, Galais MP, Ben Abdelghani M, Michel P, Metges JP, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, El Hajbi F, Samalin E, Hiret S, Delaine-Clisant S, Mariette C, Penel N, Piessen G, Le Deley MC.

Eur J Cancer. 2019 Apr;111:12-20. doi: 10.1016/j.ejca.2019.01.016. Epub 2019 Feb 22.

PMID:
30798084
36.

The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer.

Kaderbhaï C, Tharin Z, Ghiringhelli F.

Cancers (Basel). 2019 Feb 10;11(2). pii: E201. doi: 10.3390/cancers11020201. Review.

37.

Nouvelles stratégies innovantes en immunothérapie.

Ghiringhelli F.

Bull Cancer. 2018 Dec;105 Suppl 1:S101-S112. doi: 10.1016/S0007-4551(18)30395-3. Review. French.

PMID:
30595191
38.

The Direct Conversion of α-Hydroxyketones to Alkynes.

Ghiringhelli F, Nattmann L, Bognar S, van Gemmeren M.

J Org Chem. 2019 Jan 18;84(2):983-993. doi: 10.1021/acs.joc.8b02941. Epub 2019 Jan 2.

PMID:
30566357
39.

Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer.

Ghiringhelli F, Truntzer C.

Oncotarget. 2018 Nov 27;9(93):36547-36548. doi: 10.18632/oncotarget.26389. eCollection 2018 Nov 27. No abstract available.

40.

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V.

J Immunother Cancer. 2018 Nov 19;6(1):123. doi: 10.1186/s40425-018-0438-3.

41.

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.

Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C.

JAMA Oncol. 2019 Jan 1;5(1):83-90. doi: 10.1001/jamaoncol.2018.4465.

PMID:
30422156
42.

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F.

Br J Cancer. 2018 Oct;119(8):950-960. doi: 10.1038/s41416-018-0220-9. Epub 2018 Oct 15. Erratum in: Br J Cancer. 2019 Jul;121(3):283.

43.

Bevacizumab-based Chemotherapy for Poorly-differentiated Neuroendocrine Tumors.

Collot T, Fumet JD, Klopfenstein Q, Vincent J, Bengrine L, Ghiringhelli F.

Anticancer Res. 2018 Oct;38(10):5963-5968. doi: 10.21873/anticanres.12943.

PMID:
30275226
44.

A Randomized Phase II Trial (TAMIGA) Evaluating the Efficacy and Safety of Continuous Bevacizumab Through Multiple Lines of Treatment for Recurrent Glioblastoma.

Brandes AA, Gil-Gil M, Saran F, Carpentier AF, Nowak AK, Mason W, Zagonel V, Dubois F, Finocchiaro G, Fountzilas G, Cernea DM, Chinot O, Anghel R, Ghiringhelli F, Beauchesne P, Lombardi G, Franceschi E, Makrutzki M, Mpofu C, Urban HJ, Pichler J.

Oncologist. 2019 Apr;24(4):521-528. doi: 10.1634/theoncologist.2018-0290. Epub 2018 Sep 28.

PMID:
30266892
45.

Transcriptional Programs Underlying Cd4 T Cell Differentiation and Functions.

Chalmin F, Humblin E, Ghiringhelli F, Végran F.

Int Rev Cell Mol Biol. 2018;341:1-61. doi: 10.1016/bs.ircmb.2018.07.002. Epub 2018 Aug 20. Review.

PMID:
30262030
46.

FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer.

Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, de Gramont A, Chibaudel B.

World J Clin Oncol. 2018 Sep 14;9(5):110-118. doi: 10.5306/wjco.v9.i5.110.

47.

LPCAT2 controls chemoresistance in colorectal cancer.

Cotte AK, Aires V, Ghiringhelli F, Delmas D.

Mol Cell Oncol. 2018 Apr 11;5(3):e1448245. doi: 10.1080/23723556.2018.1448245. eCollection 2018.

48.

Fluorouracil and bevacizumab plus anakinra for patients with metastatic colorectal cancer refractory to standard therapies (IRAFU): a single-arm phase 2 study.

Isambert N, Hervieu A, Rébé C, Hennequin A, Borg C, Zanetta S, Chevriaux A, Richard C, Derangère V, Limagne E, Blanc J, Bertaut A, Ghiringhelli F.

Oncoimmunology. 2018 Aug 1;7(9):e1474319. doi: 10.1080/2162402X.2018.1474319. eCollection 2018.

49.

Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature.

Delanne J, Nambot S, Chassagne A, Putois O, Pelissier A, Peyron C, Gautier E, Thevenon J, Cretin E, Bruel AL, Goussot V, Ghiringhelli F, Boidot R, Tran Mau-Them F, Philippe C, Vitobello A, Demougeot L, Vernin C, Lapointe AS, Bardou M, Luu M, Binquet C, Lejeune C, Joly L, Juif C, Baurand A, Sawka C, Bertolone G, Duffourd Y, Sanlaville D, Pujol P, Geneviève D, Houdayer F, Thauvin-Robinet C, Faivre L.

Eur J Med Genet. 2019 Jun;62(6):103529. doi: 10.1016/j.ejmg.2018.08.010. Epub 2018 Aug 28. Review.

PMID:
30165243
50.

Exome Analysis Reveals Genomic Markers Associated with Better Efficacy of Nivolumab in Lung Cancer Patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F.

Clin Cancer Res. 2019 Feb 1;25(3):957-966. doi: 10.1158/1078-0432.CCR-18-1940. Epub 2018 Aug 28.

PMID:
30154227

Supplemental Content

Loading ...
Support Center